keyboard_arrow_up

2009-2018 Investigation Report on China Pregabalin Industry

RnRMarketResearch.com adds report “Investigation Report on China Pregabalin Market, 2009-2018” to its store.

Neuropathic pain is caused by damage or pathological changes of nervous system. Its main features are dull pain, aestus and tingling. About 1% of people worldwide have neuropathic pain. Epileptic seizures are the result of excessive and abnormal cortical nerve cell activity in the brain. It is a group of longterm neurological disorders. As a chronic disease, epilepsy can seriously damage patients’ mental and physical health and become a huge burden for their families and the society. According to WHO, the global number of epilepsy patients is higher than 50 million and over 9 million of them are in China.

Pfizer Co., Ltd. submitted registration application for Pregabalin (produced by Pfizer with the trade name “Lyrica”) in the U.S. in 2003. In December 2004 pregabalin was approved by FDA to treat diabetic neuropathic pain and postherpetic neuralgia. It is the first drug approved to treat both the two diseases in the U.S.A. and in Europe. In June 2005, pregabalin was approved to be used in the adjuvant treatment of adults with partialonset seizures in epilepsy. After that, it was approved to treat generalized anxiety disorder and fibromyalgia syndrome successively. Time Magazine named pregabalin as one of the “Top 10 Medical Progress” in 2007. Total revenue of pregabalin is more than USD 20 billion. The global sales revenue of Lyrica was approximately USD 4.16 billion, increased by 13% YOY.

Inquire for a discount on this report @ http://www.rnrmarketresearch.com/contacts/discount?rname=155333 .

In 2010 Lyrica was approved to China. According to CRI’s market investigation, the sales revenue of Lyrica in Chinese sample hospital market grew over 100 times from 2010 to 2013. Due to Lyrica’s success, many pharmaceutical manufacturers in China begin to apply for pregabalin production. Chongqing Succeway Pharmaceutical Co., Ltd. received production license in 2013. Lyrica produced by Pfizer is expected to be the main product in Chinese market in recent years. However, its market share will decline in 2014 due to competition from relatively cheap homemade drugs.

Based on its development in the past, incidence of epilepsy is doomed to increase, which leads to a bright future for pregabalin market in China.

Complete report is available @ http://www.rnrmarketresearch.com/investigation-report-on-china-pregabalin-market-2009-2018-market-report.html .

Through this report, the readers can acquire the following information:

  • Sales price of Pregabalin in Hospital Market in China
  • Major Pregabalin Manufacturers in China
  • Patent Status of Pregabalin in China
  • Share of Pregabalin in Different Dosage Forms in China Hospital Market

The following enterprises and people are recommended to purchase this report:

  • Antiepileptic Drug Manufacturers
  • Investors /Research Agencies Focusing on Nervous System Drug Market

Purchase a copy of this report @ http://www.rnrmarketresearch.com/contacts/purchase?rname=155333 .

Browse Central Nervous System Drugs Industry Reports @ http://www.rnrmarketresearch.com/reports/life-sciences/pharmaceuticals/diseases-treatment/central-nervous-system-drugs .

About Us:

RnRMarketResearch.com is an online database of market research reports offer in-depth analysis of over 5000 market segments. The library has syndicated reports by leading market research publishers across the globe and also offer customized market research reports for multiple industries. Not limited to industry reports covering telecommunication, healthcare, pharmaceutical, financial services, energy, technology, real estate, logistics, F&B , media and more.

Follow Us On

Twitter : https://twitter.com/#!/RnRMR

Facebook : http://www.facebook.com/pages/RnR-Market-Research/413488545356345

Google Plus : https://plus.google.com/u/0/104156468549256253075/